Liberia Visitors Alerted to Continuing Clade II Mpox Outbreak

The U.S. Centers for Disease Control and Prevention (CDC) today issued a Level 2 Travel Health Notice, advising travelers to practice enhanced precautions due to the ongoing clade II Mpox outbreak in Liberia.

As of early November 2025, the West African country of Liberia has reported 2,447 suspected cases of Mpox since the outbreak began in September 2024. The virus is transmitted between clade IIa and clade IIb strains, with local human-to-human spread observed.

There are also cross-border links to neighboring countries such as Sierra Leone.

This CDC travel advisory, effective as of January 14, 2026, emphasizes the transmission of clade II Mpox from person to person, including through sexual and other intimate contact. The CDC has noted that both males and females are affected approximately equally.

To combat the outbreak, the Liberian Ministry of Health, in collaboration with partners such as the World Health Organization and the Africa CDC, has implemented enhanced response measures. These measures include a nationwide vaccination campaign to administer 42,720 vaccine doses to high-risk groups by the end of January 2026.

The CDC advises travelers to Liberia to review this notice and consider getting vaccinated against Mpox (JYNNEOS®) if they plan to engage in activities that may increase their risk.

Last year, approximately 80,000 international tourists visited Liberia.

This U.S. FDA-approved vaccine is offered at various travel clinics throughout the USA.